Isatuximab

Definition

A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.

NCIT:C90578 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as Hu 38SB19, Immunoglobulin G1, Anti-(Human CD38 Antigen) (Human-mus musculus Monoclonal HU38SB19 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HU38SB19 Light Chain, Dimer, ISATUXIMAB, Isatuximab-irfc, SAR 650984, SAR-650984, SAR650984, Sarclisa — per NCIT

Also identified as

ATC L01FC02 per RXNORM
NCIT NCIT:C90578 per NCIT
SCTID 860763005 per RXNORM
SCTID 860769009 per RXNORM
UNII R30772KCU0 per RXNORM

Indications

Disease	Relation	Source
Multiple myeloma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Lymphoid system	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.